Lineage Cell Therapeutics, Inc. — Cyborg Score 6/10

Strategic Profile

The company's business strategy is to efficiently leverage its technology platform and its development and manufacturing capabilities to advance its programs internally or in conjunction with strategic partners to further enhance their value and probability of success. OpRegen's uniquely durable treatment effects last up to 24 months, with a 36-month data update from Roche and Genentech forthcoming. The company received a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits from Factor Bioscience Inc., marking a successful milestone in their strategic collaboration.

Cyborg Score Rationale

Lineage demonstrates solid fundamentals with strategic partnerships (Roche/Genentech), promising clinical data for lead candidate OpRegen, and a diversified pipeline targeting high-unmet-need indications. However, clinical-stage status, minimal revenue ($9.5M in 2024), significant losses (-$18.6M), and execution risk constrain the score. Recent hypoimmunity iPSC advancement and strong analyst ratings offset concerns.

Top Insights

• Lead program OpRegen (in collaboration with Roche/Genentech) shows durable 24-month treatment durability for age-related macular degeneration, validating the retinal pigment epithelium transplant mechanism of action
• Diversified pipeline spanning ophthalmology (OpRegen, PNC1), neurology (OPC1 for spinal cord injury), oncology (VAC2 for lung cancer), and emerging platforms reduces single-program risk
• Strategic advancement with Factor Bioscience hypoimmunity iPSC technology addresses critical allogeneic cell therapy challenge of immune rejection, potentially enabling better cell engraftment
• Company trades at ~$225M market cap with minimal revenue; success heavily dependent on Roche/Genentech OpRegen regulatory approval and clinical milestone achievement

Named Competitors

• CAR-T cell therapy platform — Autologous cell therapy for oncology
• iPSC-derived cell therapies — Off-the-shelf allogeneic cell therapies
• Regenerative medicine platform — iPSC-derived cell replacement therapies
• RPE cell replacement therapies — Retinal pigment epithelium cell therapy for AMD

Recent Developments

• (January 2026) Received novel hypoimmunity-edited iPSC line from Factor Bioscience, advancing off-the-shelf cell therapy capabilities
• (November 2025) Company publishes stockholder letter highlighting 2025 achievements and 2026 corporate outlook
• (August 2025) Announced receipt of hypoimmunity iPSC line and reported Q2 2025 financial results with positive OpRegen clinical progress
• (November 2024) Achieved first milestone under worldwide collaboration agreement with Genentech

Open the full interactive Lineage Cell Therapeutics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.